Relationship between Advanced Glycation End-products, Serum Carnosinase-1 and Diabetic Nephropathy and Diabetic Retinopathya
Advanced Glycation End-products, Carnosinase-1 and Diabetic Microangiopathy
Abstract
Introduction: This article analyzed the relationship between serum advanced glycation end-products (AGEs), carnosinase-1 (CN-1) and diabetic nephropathy (DN) and diabetic retinopathy (DR).
Material and Method: 150 patients with type 2 diabetes mellitus (DM2) were grouped: DN and non-DN, DR and non-DR groups. Fasting venous blood was collected, and serum levels of AGEs and CN-1 were detected. Pearson’s correlation (PC) test was adopted for analyzing their correlation with DN and DR, and multivariate Logistic regression (MLR) analysis was adopted.
Result: There were 48 DN cases, 102 non-DN cases, 20 DR cases, and 130 non-DR cases in 150 patients with DM2. As against the non-DN group, the serum levels of AGEs and CN-1 in the subjects with DN were markedly increased. As against the non-DR group, the serum levels of AGEs and CN-1 in the subjects with DR were also markedly increased. The results of correlation analysis revealed that the levels of serum AGEs and CN-1 were positively correlated with the occurrence of DN and DR. Serum AGEs and CN-1 levels were independent risk factors (IRF) for DN and DR (all P <0.05).
Conclusion: AGEs and CN-1 may become new targets for the diagnosis and remedy of diabetic microvascular complications.
Copyright (c) 2025 Yu Rong
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.